R&D News | pharmaphorum

News

23andMe study explains variable results with obesity drugs

Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.

News

Graphic of pile of gold coins and green shoots on blue background

Syneron raises $150m for macrocyclics, and other financings

Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.

News

Jeito's founder and president, Dr Rafaèle Tordjman

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.

News

EU invests €30m to fight antimicrobial resistance

The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AI giant Anthropic buys Coefficient Bio for $400m

Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.

23andMe study explains variable results with obesity drugs

Syneron raises $150m for macrocyclics, and other financings

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

EU invests €30m to fight antimicrobial resistance

Gilead strikes again, penning $5bn deal to buy Tubulis

AI giant Anthropic buys Coefficient Bio for $400m

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks